Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPT Duration in CTO PCI
NCT06175377Not yet recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of clopidogrel in Chronic total occlusion of the coronary artery (CTO) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Bleeding events at 12 months and Ischemic events at 12 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
clopidogrel
03
Conditions
Chronic total occlusion of the coronary artery (CTO)
Beyond the preview
Go deeper on NCT06175377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175377.